JP2014530244A - 血管漏出症候群および癌を治療する方法 - Google Patents

血管漏出症候群および癌を治療する方法 Download PDF

Info

Publication number
JP2014530244A
JP2014530244A JP2014535979A JP2014535979A JP2014530244A JP 2014530244 A JP2014530244 A JP 2014530244A JP 2014535979 A JP2014535979 A JP 2014535979A JP 2014535979 A JP2014535979 A JP 2014535979A JP 2014530244 A JP2014530244 A JP 2014530244A
Authority
JP
Japan
Prior art keywords
patient
hptpβ
binding agent
cancer
ecd binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2014535979A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014530244A5 (OSRAM
Inventor
ピーターズ，ケヴィン
ケヴィン ピーターズ，
ロバート シャルヴィッツ，
ロバート シャルヴィッツ，
Original Assignee
エアピオ セラピューティックス， インコーポレイテッド
エアピオ セラピューティックス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エアピオ セラピューティックス， インコーポレイテッド, エアピオ セラピューティックス， インコーポレイテッド filed Critical エアピオ セラピューティックス， インコーポレイテッド
Publication of JP2014530244A publication Critical patent/JP2014530244A/ja
Publication of JP2014530244A5 publication Critical patent/JP2014530244A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014535979A 2011-10-13 2012-10-15 血管漏出症候群および癌を治療する方法 Withdrawn JP2014530244A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161546697P 2011-10-13 2011-10-13
US201161546748P 2011-10-13 2011-10-13
US61/546,697 2011-10-13
US61/546,748 2011-10-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017130652A Division JP2017165786A (ja) 2011-10-13 2017-07-03 血管漏出症候群および癌を治療する方法

Publications (2)

Publication Number Publication Date
JP2014530244A true JP2014530244A (ja) 2014-11-17
JP2014530244A5 JP2014530244A5 (OSRAM) 2015-12-03

Family

ID=48082581

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2014535979A Withdrawn JP2014530244A (ja) 2011-10-13 2012-10-15 血管漏出症候群および癌を治療する方法
JP2017130652A Withdrawn JP2017165786A (ja) 2011-10-13 2017-07-03 血管漏出症候群および癌を治療する方法
JP2017143622A Pending JP2017200947A (ja) 2011-10-13 2017-07-25 血管漏出症候群および癌を治療する方法
JP2019087483A Active JP6706367B2 (ja) 2011-10-13 2019-05-07 血管漏出症候群および癌を治療する方法
JP2019115666A Withdrawn JP2019151673A (ja) 2011-10-13 2019-06-21 血管漏出症候群および癌を治療する方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2017130652A Withdrawn JP2017165786A (ja) 2011-10-13 2017-07-03 血管漏出症候群および癌を治療する方法
JP2017143622A Pending JP2017200947A (ja) 2011-10-13 2017-07-25 血管漏出症候群および癌を治療する方法
JP2019087483A Active JP6706367B2 (ja) 2011-10-13 2019-05-07 血管漏出症候群および癌を治療する方法
JP2019115666A Withdrawn JP2019151673A (ja) 2011-10-13 2019-06-21 血管漏出症候群および癌を治療する方法

Country Status (10)

Country Link
US (4) US20130095065A1 (OSRAM)
EP (2) EP3505182A1 (OSRAM)
JP (5) JP2014530244A (OSRAM)
CN (1) CN104039351A (OSRAM)
AU (1) AU2012323856B2 (OSRAM)
BR (1) BR112014008819A8 (OSRAM)
CA (1) CA2850830A1 (OSRAM)
HK (1) HK1201178A1 (OSRAM)
MX (2) MX363351B (OSRAM)
WO (1) WO2013056240A1 (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007237096C1 (en) 2006-04-07 2012-12-13 EyePoint Pharmaceuticals, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US9096555B2 (en) * 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
CA2748765C (en) 2009-07-06 2014-07-22 Akebia Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
ES2644998T3 (es) 2009-11-06 2017-12-01 Aerpio Therapeutics Inc. Métodos para aumentar la estabilización del factor-1 alfa inducible por hipoxia
HK1201196A1 (en) 2011-10-13 2015-08-28 Aerpio Therapeutics, Inc. Treatment of ocular disease
EP3505182A1 (en) 2011-10-13 2019-07-03 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
GB2516561B (en) 2013-03-15 2016-03-09 Aerpio Therapeutics Inc Compositions, formulations and methods for treating ocular diseases
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
EP2832746B1 (en) 2013-07-29 2018-07-18 Samsung Electronics Co., Ltd Anti-Ang2 antibody
KR102196450B1 (ko) 2013-09-17 2020-12-30 삼성전자주식회사 Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제
ES2739625T3 (es) 2014-02-19 2020-02-03 Aerpio Therapeutics Inc Proceso para la preparación de N-bencil-3-hidroxi-4-sustituido-piridin-2-(1H)-onas
CN106456614A (zh) 2014-03-14 2017-02-22 爱尔皮奥治疗有限公司 HPTP‑β抑制剂
WO2016022813A1 (en) 2014-08-07 2016-02-11 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of tie-2
EP4015652B1 (en) 2015-06-03 2025-08-06 Aelan Cell Technologies, Inc. Companion methods or il-2-based therapies and mesenchymal stem cell-based therapies
MX387804B (es) 2015-09-23 2025-03-19 Aerpio Therapeutics Inc Metodos para tratar presion intraocular con activadores de tie-2
WO2018017714A1 (en) 2016-07-20 2018-01-25 Aerpio Therapeutics, Inc. HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
CA3052474A1 (en) 2017-02-09 2018-08-16 Fred Hutchinson Cancer Research Center Biomarkers and uses thereof for selecting immunotherapy intervention
US12006354B2 (en) 2017-05-24 2024-06-11 Novartis Ag Antibody-IL2 engrafted proteins and methods of use in the treatment of cancer
EP3856245A4 (en) 2018-09-24 2022-10-26 EyePoint Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - ß (VE-PTP) AND VEGF
JP7564824B2 (ja) 2019-04-29 2024-10-09 アイポイント ファーマシューティカルズ， インコーポレイテッド シュレム管を標的とするＴｉｅ－２活性化物質
EP3962466A4 (en) * 2019-05-02 2023-01-25 Biogen Chesapeake LLC METHODS OF TREATMENT OF PERSONS WITH CONtusions Of The Central Nervous System
GB2589400A (en) 2019-06-24 2021-06-02 Aerpio Pharmaceuticals Inc Formulations of tie-2 activators and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009533337A (ja) * 2006-04-07 2009-09-17 ザ プロクター アンド ギャンブル カンパニー ヒトタンパク質チロシンホスファターゼβ（ＨＰＴＰβ）に結合する抗体及びその使用
WO2011087066A1 (ja) * 2010-01-14 2011-07-21 株式会社三和化学研究所 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬

Family Cites Families (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4673641A (en) 1982-12-16 1987-06-16 Molecular Genetics Research And Development Limited Partnership Co-aggregate purification of proteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
DK0574048T3 (da) 1992-03-13 2002-12-16 Organon Teknika Bv Peptider og nucleinsyresekvenser relateret til Epstein-Barr-virus
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5770565A (en) 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
US5688781A (en) 1994-08-19 1997-11-18 Bristol-Myers Squibb Company Method for treating vascular leak syndrome
WO1996031598A1 (en) 1995-04-06 1996-10-10 Regeneron Pharmaceuticals, Inc. Tie-2 ligands, methods of making and uses thereof
DE69638058D1 (de) 1995-06-15 2009-11-26 Crucell Holland Bv Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie
US20030040463A1 (en) 1996-04-05 2003-02-27 Wiegand Stanley J. TIE-2 ligands, methods of making and uses thereof
AU5154098A (en) 1996-10-31 1998-05-22 Duke University Soluble tie2 receptor
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
DK1325932T5 (da) 1997-04-07 2005-10-03 Genentech Inc Anti-VEGF antistoffer
US5919813C1 (en) 1998-03-13 2002-01-29 Univ Johns Hopkins Med Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
US5980929A (en) 1998-03-13 1999-11-09 Johns Hopkins University, School Of Medicine Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischmemia or ocular inflammation
AR022303A1 (es) 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
ES2199804T3 (es) 1999-03-26 2004-03-01 Regeneron Pharmaceuticals, Inc. Modulacion de la permeabilidad vascular por medio de activadores del receptor tie2.
US6455035B1 (en) 1999-03-26 2002-09-24 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
EP1046715A1 (en) 1999-04-23 2000-10-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2
AU5062500A (en) 1999-04-26 2000-11-10 Amersham Pharmacia Biotech Ab Primers for identifying typing or classifying nucleic acids
CA2372053C (en) 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
WO2000070030A1 (en) 1999-05-19 2000-11-23 Amgen Inc. Crystal of a lymphocyte kinase-ligand complex and methods of use
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US6589758B1 (en) 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
AU784231B2 (en) 2000-06-23 2006-02-23 Schering Aktiengesellschaft Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/tie receptor function and their use (II)
US6316109B1 (en) 2000-09-21 2001-11-13 Ppg Industries Ohio, Inc. Aminoplast-based crosslinkers and powder coating compositions containing such crosslinkers
HUP0303085A2 (hu) 2000-09-27 2003-12-29 The Procter & Gamble Co. Melanokortin receptor ligandumok és ezeket tartalmazó gyógyszerkészítmények
US6455026B1 (en) 2001-03-23 2002-09-24 Agy Therapeutics, Inc. Use of protein tyrosine phosphatase zeta as a biomolecular target in the treatment and visualization of brain tumors
CA2461896C (en) 2001-09-28 2012-09-18 Santen Pharmaceutical Co., Ltd. Injections for eye tissues containing drug bonded to polyethylene glycol
US20050260132A1 (en) 2001-10-17 2005-11-24 Daniel Chin Monoclonal antibodies directed to receptor protein tyrosine phosphatase zeta
WO2003034990A2 (en) 2001-10-25 2003-05-01 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
WO2003047611A2 (en) 2001-12-04 2003-06-12 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Ptp10d, tec and edtp involved in triglycerid-metabolism
US20030158083A1 (en) 2002-02-08 2003-08-21 The Procter & Gamble Company Method of effecting angiogenesis by modulating the function of a novel endothelia phosphatase
US20030215899A1 (en) 2002-02-13 2003-11-20 Ceptyr, Inc. Reversible oxidation of protein tyrosine phosphatases
AU2003229627A1 (en) 2002-04-08 2003-10-20 Max-Planck-Gesellschaft Zur Ve-ptp as regulator of ve-cadherin mediated processes or disorders
RU2376029C2 (ru) 2002-04-25 2009-12-20 Юниверсити Оф Коннектикут Хелт Сентер Применение белков теплового шока для улучшения терапевтического эффекта невакцинного лечебного воздействия
WO2003092611A2 (en) 2002-05-03 2003-11-13 Regeneron Pharmaceuticals, Inc. Methods of inducing formation of functional and organized lymphatic vessels
US7507568B2 (en) 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US7226755B1 (en) 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
US6930117B2 (en) 2002-11-09 2005-08-16 The Procter & Gamble Company N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones
US20040167183A1 (en) 2003-02-20 2004-08-26 The Procter & Gamble Company Phenethylamino sulfamic acids
US7718377B2 (en) 2003-05-29 2010-05-18 Kyoto Pharmaceutical Industries, Ltd. Insulin resistance curative and method of screening the same
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050059639A1 (en) 2003-09-11 2005-03-17 Wei Edward T. Ophthalmic compositions and method for treating eye discomfort and pain
US20050158320A1 (en) 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
US8298532B2 (en) 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
RS54199B1 (sr) 2004-03-15 2015-12-31 Janssen Pharmaceutica Nv Postupak za dobijanje intermedijera jedinjenja korisnih kao modulatori opioidnih receptora
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
ATE456579T1 (de) 2004-07-20 2010-02-15 Genentech Inc Angiopoietin-like 4 protein hemmer kombinationen und deren verwendung
EP2457578B1 (en) 2004-09-28 2015-08-19 Aprogen, Inc. Chimeric molecule comprising angiopoietin-1 and a coiled-coil domain for use in treating penile erectile dysfunction
JP4884395B2 (ja) 2004-12-21 2012-02-29 アストラゼネカ エービー アンジオポエチン−２に対する抗体およびそれらの使用
RU2007135216A (ru) 2005-02-23 2009-03-27 Мерримак Фармасьютикалз, Инк. (Us) Биспецифические связывающие агенты для модулирования биологической активности
US20120237442A1 (en) 2005-04-06 2012-09-20 Ibc Pharmaceuticals, Inc. Design and Construction of Novel Multivalent Antibodies
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US7893040B2 (en) 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007033216A2 (en) 2005-09-12 2007-03-22 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
US20070134234A1 (en) 2005-09-29 2007-06-14 Viral Logic Systems Technology Corp. Immunomodulatory compositions and uses therefor
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
US20090123474A1 (en) 2005-12-15 2009-05-14 Astrazeneca Ab Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer
EP1981520A2 (en) 2006-01-30 2008-10-22 (OSI) Eyetech, Inc. Combination therapy for the treatment of neovascular disorders
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
SG172686A1 (en) 2006-03-08 2011-07-28 Archemix Corp Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders
WO2007113648A2 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
US7608261B2 (en) 2006-06-16 2009-10-27 Regeneron Pharmacuticals, Inc. VEGF antagonist formulations suitable for intravitreal administration
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US20130023542A1 (en) 2006-06-27 2013-01-24 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
DK2076290T3 (en) 2006-10-27 2017-01-23 Sunnybrook Health Sciences Center MULTIMERIC TIE 2 AGONISTS AND APPLICATIONS THEREOF IN STIMULATING ANGIOGENESIS
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
WO2008127727A1 (en) 2007-04-13 2008-10-23 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
WO2009003110A2 (en) 2007-06-26 2008-12-31 Children's Medical Center Corporation Metap-2 inhibitor polymersomes for therapeutic administration
US20090002289A1 (en) * 2007-06-28 2009-01-01 Boundary Net, Incorporated Composite display
JP5171948B2 (ja) 2007-06-29 2013-03-27 メルク・シャープ・アンド・ドーム・コーポレーション Ｍｄｌ−１の使用
RU2010120674A (ru) 2007-10-22 2011-11-27 Шеринг Корпорейшн (US) Полностью человеческие анти-vegf-антитела и способы их применения
US9403789B2 (en) 2008-02-21 2016-08-02 Sequoia Pharmaceuticals, Inc. Benzofuran-containing amino acid inhibitors of cytochrome P450
US8293714B2 (en) 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
KR101737466B1 (ko) 2008-06-25 2017-05-18 에스바테크 - 어 노바티스 컴파니 엘엘씨 Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
CN102272148A (zh) 2008-11-03 2011-12-07 分子组合公司 抑制vegf-a受体相互作用的结合蛋白
CN108635350A (zh) 2009-01-12 2018-10-12 爱尔皮奥治疗有限公司 治疗血管渗漏综合征的方法
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
WO2010097800A1 (en) 2009-02-26 2010-09-02 Muhammad Abdulrazik Synergistic combination of bioactive compounds for lowering of intraocular pressure
CN102340991B (zh) 2009-03-03 2014-02-26 爱尔康研究有限公司 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物
MX2011008680A (es) 2009-03-03 2011-09-08 Alcon Res Ltd Composicion farmaceutica para el suministro de compuestos inhibidores de la tirosina cinasa receptora (rtki) para los ojos.
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
CA2748765C (en) 2009-07-06 2014-07-22 Akebia Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
ES2644998T3 (es) 2009-11-06 2017-12-01 Aerpio Therapeutics Inc. Métodos para aumentar la estabilización del factor-1 alfa inducible por hipoxia
AU2010325969B2 (en) 2009-12-02 2016-10-20 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen
IL323000A (en) 2010-03-05 2025-10-01 Univ Johns Hopkins Compositions and methods for antibodies and fusion proteins targeted for immune modulation
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
EP3311835B1 (en) 2010-07-12 2021-03-24 Threshold Pharmaceuticals Inc. Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer
US20180092883A1 (en) 2010-10-07 2018-04-05 Aerpio Therapeutics, Inc. Phosphatase inhibitors for treating ocular diseases
PH12013500577B1 (en) 2010-10-07 2019-06-28 Aerpio Therapeutics Inc Compositions and methods for treating ocular edema, neovascularization and related diseases
CN103249422A (zh) 2010-12-02 2013-08-14 丸善制药株式会社 Tie2活化剂、血管内皮生长因子抑制剂、血管生成抑制剂、血管成熟剂、血管正常化剂及血管稳定剂、以及药物组合物
CA2824422A1 (en) 2011-01-13 2012-07-19 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
WO2012109673A1 (en) 2011-02-11 2012-08-16 Psivida Us, Inc. Methods of treating macular edema using antiedema therapeutics
EP3505182A1 (en) 2011-10-13 2019-07-03 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
HK1201196A1 (en) 2011-10-13 2015-08-28 Aerpio Therapeutics, Inc. Treatment of ocular disease
CN104870011A (zh) 2011-11-03 2015-08-26 托莱拉医疗股份有限公司 选择性抑制t细胞应答的抗体和方法
US20130190324A1 (en) 2011-12-23 2013-07-25 The Regents Of The University Of Colorado, A Body Corporate Topical ocular drug delivery
CA2870341A1 (en) 2012-04-13 2013-10-17 The Johns Hopkins University Treatment of ischemic retinopathies
PT2846836T (pt) 2012-05-07 2019-10-29 Allergan Inc Método de tratamento de dmi em doentes refratários à terapia anti-vegf
UA120029C2 (uk) 2012-07-13 2019-09-25 Рош Глікарт Аг Спосіб зниження в'язкості біспецифічного антитіла до vegf/ang-2 та застосування такого антитіла для лікування судинних очних захворювань
MX360824B (es) 2012-07-31 2018-11-15 Univ Texas Una combinación para inducir la formación de células beta de células de mamífero y uso de la misma.
EP2890389A1 (en) 2012-08-28 2015-07-08 Novartis AG Use of a vegf antagonist in treating ocular vascular proliferative diseases
MY177912A (en) 2012-10-11 2020-09-25 Ascendis Pharma Ophthalmology Div A/S Vegf neutralizing prodrugs for the treatment of ocular conditions
EP3721872B1 (en) 2012-11-08 2025-01-22 Clearside Biomedical Inc. Methods for the treatment of ocular disease in human subjects
WO2014079709A1 (en) 2012-11-23 2014-05-30 Ab Science Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
GB2516561B (en) 2013-03-15 2016-03-09 Aerpio Therapeutics Inc Compositions, formulations and methods for treating ocular diseases
DK2983695T3 (da) 2013-04-11 2019-09-02 Sunnybrook Res Inst Fremgangsmåder, anvendelser og sammensætninger af tie2- agonister
JP2016522250A (ja) 2013-06-20 2016-07-28 ノバルティス アーゲー 黄斑浮腫の治療におけるｖｅｇｆアンタゴニストの使用
WO2014203182A1 (en) 2013-06-20 2014-12-24 Novartis Ag Use of a vegf antagonist in treating choroidal neovascularisation
WO2015002893A1 (en) 2013-07-02 2015-01-08 The Trustees Of Columbia University In The City Of New York Clearance of bioactive lipids from membrane structures by cyclodextrins
AU2014288847A1 (en) 2013-07-11 2016-01-28 Novartis Ag Use of a VEGF antagonist in treating retinopathy of prematurity
US20160168240A1 (en) 2013-07-11 2016-06-16 Sergey AKSENOV Use of vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients
EP2832746B1 (en) 2013-07-29 2018-07-18 Samsung Electronics Co., Ltd Anti-Ang2 antibody
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
US20160252526A1 (en) 2013-10-01 2016-09-01 Sphingotec Gmbh A method for predicting the risk of getting a major adverse cardiac event
AU2014337135B2 (en) 2013-10-18 2019-09-19 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of a VEGF antagonist and an anti-CTLA-4 antibody
LT3062811T (lt) 2013-11-01 2019-05-10 Regeneron Pharmaceuticals, Inc. Intervencijos angiopoietino pagrindu cerebrinės maliarijos gydymui
DK3065761T3 (da) 2013-11-05 2020-02-17 Allergan Inc Fremgangsmåde til behandling af tilstande af øjet med en anti-vegf darpin
AU2015204674B2 (en) 2014-01-10 2020-09-03 Anaptysbio, Inc. Antibodies directed against interleukin-33 (IL-33)
ES2739625T3 (es) 2014-02-19 2020-02-03 Aerpio Therapeutics Inc Proceso para la preparación de N-bencil-3-hidroxi-4-sustituido-piridin-2-(1H)-onas
CN106456614A (zh) 2014-03-14 2017-02-22 爱尔皮奥治疗有限公司 HPTP‑β抑制剂
JP2015199733A (ja) 2014-04-04 2015-11-12 国立大学法人東北大学 眼圧降下剤
US9719135B2 (en) 2014-07-03 2017-08-01 Mannin Research Inc. Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system
WO2016022813A1 (en) 2014-08-07 2016-02-11 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of tie-2
SG11201701016WA (en) 2014-09-16 2017-03-30 Ovascience Inc Anti-vasa antibodies, and methods of production and use thereof
WO2016049183A1 (en) 2014-09-24 2016-03-31 Aerpio Therapeutics, Inc. Ve-ptp extracellular domain antibodies delivered by a gene therapy vector
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
AU2015360496B2 (en) 2014-12-11 2021-09-30 Bayer Healthcare Llc Treatment of age related macular degeneration with a small active choroidal neovascularization lesion
WO2016115092A1 (en) 2015-01-12 2016-07-21 La Jolla Institute For Allergy And Immunology Methods for targeting host vascular mechanism for therapeutic protection against hemorrhagic fever
PH12017501792B1 (en) 2015-04-02 2022-07-20 Molecular Partners Ag Recombinant binding proteins and their use
EP3341021A4 (en) 2015-08-27 2019-03-13 Celldex Therapeutics, Inc. ANTI-ALK ANTIBODIES AND METHOD OF USE THEREOF
MX387804B (es) 2015-09-23 2025-03-19 Aerpio Therapeutics Inc Metodos para tratar presion intraocular con activadores de tie-2
SG10201911226QA (en) 2015-09-23 2020-01-30 Genentech Inc Optimized variants of anti-vegf antibodies
US10894823B2 (en) 2016-03-24 2021-01-19 Gensun Biopharma Inc. Trispecific inhibitors for cancer treatment
WO2018007314A1 (en) 2016-07-04 2018-01-11 F. Hoffmann-La Roche Ag Novel antibody format
WO2018017714A1 (en) 2016-07-20 2018-01-25 Aerpio Therapeutics, Inc. HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
CN110177563A (zh) 2016-10-04 2019-08-27 阿斯克雷佩西治疗公司 用于激活tie2信号传导的化合物和方法
IT201600120314A1 (it) 2016-11-28 2018-05-28 Nuovo Pignone Tecnologie Srl Turbo-compressore e metodo di funzionamento di un turbo-compressore
US10426817B2 (en) 2017-01-24 2019-10-01 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics
WO2018218215A1 (en) 2017-05-26 2018-11-29 The Johns Hopkins University Multifunctional antibody-ligand traps to modulate immune tolerance
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
CN107602702A (zh) 2017-09-22 2018-01-19 生标（上海）医疗器械科技有限公司 一种同时靶向人p185和血管内皮生长因子的抗体及其应用
EP4609914A3 (en) 2017-11-30 2025-10-15 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
TWI731310B (zh) 2018-02-28 2021-06-21 圓祥生命科技股份有限公司 結合檢查點阻礙物作為標的治療的雙功能性蛋白質、其藥物複合體、其醫藥組成物、其核酸、及其用途
CN111867631A (zh) 2018-03-16 2020-10-30 诺华股份有限公司 治疗眼部疾病的方法
US10276202B1 (en) 2018-04-23 2019-04-30 Western Digital Technologies, Inc. Heat-assisted magnetic recording (HAMR) medium with rhodium or rhodium-based alloy heat-sink layer
IL318714A (en) 2018-05-10 2025-03-01 Regeneron Pharma Formulations that include high concentrations of VEGF receptor fusion protein
AU2019269628A1 (en) 2018-05-17 2020-12-03 The Board Of Trustees Of The Leland Stanford Junior University Receptor inhibition by phosphatase recruitment
US11066476B2 (en) 2018-09-14 2021-07-20 Shanghai tongji hospital Asymmetric bispecific antibody
EP3856245A4 (en) 2018-09-24 2022-10-26 EyePoint Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - ß (VE-PTP) AND VEGF

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009533337A (ja) * 2006-04-07 2009-09-17 ザ プロクター アンド ギャンブル カンパニー ヒトタンパク質チロシンホスファターゼβ（ＨＰＴＰβ）に結合する抗体及びその使用
WO2011087066A1 (ja) * 2010-01-14 2011-07-21 株式会社三和化学研究所 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ＬＩＦＥ ＳＣＩＥＮＣＥ, vol. 65, no. 24, JPN6016028778, 1999, pages 2573 - 2580, ISSN: 0003366647 *
生化学, vol. 82, no. 4, JPN6017007077, 2010, pages 290 - 301, ISSN: 0003509827 *

Also Published As

Publication number Publication date
AU2012323856B2 (en) 2017-05-25
US20130095065A1 (en) 2013-04-18
US10150811B2 (en) 2018-12-11
US12043664B2 (en) 2024-07-23
JP2017165786A (ja) 2017-09-21
EP3505182A1 (en) 2019-07-03
MX2014004448A (es) 2014-11-10
US20210095017A1 (en) 2021-04-01
HK1201178A1 (en) 2015-08-28
JP6706367B2 (ja) 2020-06-03
CA2850830A1 (en) 2013-04-18
EP2766043A4 (en) 2015-06-10
US20190177409A1 (en) 2019-06-13
NZ623283A (en) 2016-05-27
BR112014008819A8 (pt) 2017-09-12
JP2019151653A (ja) 2019-09-12
CN104039351A (zh) 2014-09-10
US10815300B2 (en) 2020-10-27
WO2013056240A1 (en) 2013-04-18
EP2766043A1 (en) 2014-08-20
MX363351B (es) 2019-03-20
US20180009890A1 (en) 2018-01-11
JP2017200947A (ja) 2017-11-09
AU2012323856A1 (en) 2014-04-17
JP2019151673A (ja) 2019-09-12
MX2019002983A (es) 2023-04-12
BR112014008819A2 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
JP6706367B2 (ja) 血管漏出症候群および癌を治療する方法
CN106659772B (zh) 在疾病和紊乱的治疗中调节肾酶的组合物和方法
CA2705152C (en) Anti-vegf antibody compositions and methods
ES2635316T3 (es) Anticuerpos contra ROR1 que pueden inducir muerte celular de LLC
RU2581962C2 (ru) Нацеленные средства связывания, направленные на dll4, и их применение
EP3252079B1 (en) Antibodies that bind human protein tyrosine phosphatase beta (hptp-beta) and uses thereof
KR102476846B1 (ko) 항―ｃ―ＭＥＴ 항체 및 이의 용도
US20140322242A1 (en) Materials and methods for the prevention and treatment of cancer
JP7788736B2 (ja) 疾患及び障害の治療及び予防のための抗レナラーゼ抗体
US20210355235A1 (en) Compositions and Methods For Treating Cancer with Anti-Renalase antibodies and Anti-PD1 antibodies
NZ623283B2 (en) Methods for treating vascular leak syndrome and cancer
KR20250162915A (ko) 항 muc1 항체-약물 콘주게이트 투여에 의한 약제 저감수성 암의 치료 방법

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20150303

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151014

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151014

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160727

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170703

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170710

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20170712